From Earlier: CHMP Recommends Granting of Marketing Authorization for ZALTRAP

Sanofi

and Regeneron Pharmaceuticals, Inc.

today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended the granting of marketing authorization for ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. The European Commission now needs to ratify the positive opinion from CHMP to grant marketing authorization of ZALTRAP in all 27 European Union member countries.  A decision is expected from the European Commission in the first quarter of 2013.  The CHMP opinion was based on data from the pivotal VELOUR trial. "We are pleased that CHMP has supported our ZALTRAP application.  This brings us one step closer to bringing this novel treatment with a proven survival benefit to colorectal cancer patients in Europe," said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi Oncology. "It is gratifying to see the years of effort that went into designing and developing the angiogenesis inhibitor ZALTRAP translate into a clinical benefit for patients